- Aimed Bio advances clinical development and commercialization of 가상 바카라 novel drug candidate
- 가상 바카라 of rare and intractable diseases treatment: Strategic partnership for next-generation new drug underway
[by Lee, Young Sung] SK Plasma, a company specializing in blood-derived products, is actively working on the development of next-generation targeted anticancer drugs.
SK Plasma announced on June 9 that it has entered into a co-development and licensing agreement for 가상 바카라-based anticancer drugs with Aimed Bio, a company specializing in the development of antibody-drug conjugates (가상 바카라s).
This marks the first instance in which SK Plasma, traditionally focused on rare and incurable disease treatments, has ventured into the development of 가상 바카라-based anticancer drugs.
Under the agreement, the two companies will collaborate on the development of 가상 바카라-based anticancer treatment candidates targeting ROR1, a protein expressed in various cancer types. Aimed Bio will be responsible for basic research and candidate substance discovery, while SK Plasma will handle development activities during the clinical and commercialization stages. ROR1 is an antigen that is overexpressed in multiple solid tumors as well as hematologic malignancies.
가상 바카라s are a next-generation targeted anticancer treatment that combines antibodies with potent cytotoxic agents to selectively eliminate cancer cells.
Unlike conventional chemotherapy, which can even harm healthy cells, 가상 바카라 therapy has the advantage of selectively binding to specific antigens on the surface of cancer cells and delivering the cytotoxic agent directly to these cells to kill the tumor. This approach is considered an innovative treatment, as it minimizes damage to healthy tissues while providing potent anticancer effects.
According to the global market research firm GlobalData, the global 가상 바카라 market is projected to expand significantly, growing from around USD 14 billion (approximately KRW 18.9 trillion) in 2023 to an estimated USD 112 billion by 2030.
Aimed Bio is a company that has proven its technological competitiveness in the 가상 바카라 field through a range of research achievements and multiple global technology transfer agreements.
“As Aimed Bio is a research and development-focused company, collaboration with partners that have clinical and licensing capabilities is crucial for the commercialization of novel drug candidates,” expressed Her Nam-gu, CEO of Aimed Bio. “SK Plasma possesses a deep understanding of biopharmaceuticals, as well as valuable experience and know-how accumulated from conducting domestic and international clinical trials and business development efforts. This partnership will increase the prospects for subsequent clinical trials and global commercialization of 가상 바카라-based new drugs,” he added.
SK Plasma’s strategy is to gradually expand its biopharmaceutical portfolio, focusing on the treatment of rare and intractable diseases and including 가상 바카라-based anticancer drugs.
In 2021, 가상 바카라 Plasma made a strategic investment in Curocell, a company engaged in the development of CAR-T (Chimeric Antigen Receptor T-cell) immune cell-based anticancer treatment. Curocell recently completed Phase 2 clinical trials for its next-generation CAR-T treatment, ‘RIMQARTO (Anbal-cel),’ and has submitted an application for product approval in Korea. The treatment is currently undergoing evaluation for drug reimbursement.
“Co-development with a partner like Aimed Bio, which has demonstrated strong research expertise and technological potential, holds great strategic significance in expanding our biopharmaceutical portfolio to include 가상 바카라s,” stated Kim Seung-joo, CEO of SK Plasma. “We will actively pursue further collaborations with companies that possess innovative technologies aimed at improving treatment accessibility in the field of rare and intractable diseases.”
On the other hand, Aimed Bio is a spin-off from Samsung Medical Center, established in 2018 on the foundation of more than 30 years of research by Professor Nam Do-hyun, a globally recognized expert in brain tumors. The company boasts a big data-driven target discovery platform, an in-house antibody development platform, a preclinical evaluation platform utilizing PDC/PDX models, and a proprietary linker-payload platform. Earlier this year, Aimed Bio successfully transferred technology for an 가상 바카라 novel drug candidate to Biohaven in the United States.